Shivkant Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shivkant Patel has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ashim Kumar Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391 760, Gujarat, India
3 shared publications- Ashim Kumar Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara-391760, Gujarat, India
3 shared publications - Dhanya B. Sen
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
3 shared publications - Dillip Kumar Dash
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
3 shared publications - Aarti S. Zanwar
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara, 391760, Gujarat, India
1 shared publication Ashish Shah
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391 760, Gujarat, India
1 shared publication
Latest Publications
- 20 April 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (4)
Quality by Design Guided Stability‐Indicating HPLC Method for Concurrent Analysis of Clotrimazole and Mometasone Furoate in Cream Formulation
Clotrimazole (CLOT) is an antifungal and mometasone furoate (MOMF), a corticosteroid used to treat skin infections effectively by killing the pathogenic fungus and reducing inflammation. This work aimed to develop a stability‐indicating liquid chromatographic method for the concurrent quantification of MOMF and CLOT employing a design‐of‐experiment strategy. The elution solvent used to test CLOT and MOMF was a combination of 60:40 v/v acetonitrile and phosphate buffer (pH 4.0). A Shimpack ODS C18 column (4.6 mm × 250 mm, 5 µm) was utilized for this purpose. This approach was tested with a detection wavelength of 249 nm and a flow rate of 1 mL/min. The mobile phase was optimized utilizing a 3 2 full factorial design (quadratic model). The International Conference on Harmonization strategies were used to validate the methodology. The cream formulation comprising both the drugs underwent force degradation study. CLOT was determined to have an acceptable linearity range of 50–600 µg/mL, whereas MOMF had a linearity range of 5–60 µg/mL. The method demonstrated good sensitivity, with detection limit and quantification limit 3.97 and 12.04 µg/mL for CLOT along with 1.14 and 3.45 µg/mL for MOMF. The established methodology was determined to be both accurate (recovery between 98% and 102%) and precise (% RSD < 2). The degradation studies aimed to confirm the efficient separation of CLOT and MOMF from their degradation products. Chromatograms of stressed samples confirmed that degradation products did not interfere with the peaks of the active components.
- 20 April 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (4)
Quality by Design Guided Stability‐Indicating HPLC Method for Concurrent Analysis of Clotrimazole and Mometasone Furoate in Cream Formulation
Clotrimazole (CLOT) is an antifungal and mometasone furoate (MOMF), a corticosteroid used to treat skin infections effectively by killing the pathogenic fungus and reducing inflammation. This work aimed to develop a stability‐indicating liquid chromatographic method for the concurrent quantification of MOMF and CLOT employing a design‐of‐experiment strategy. The elution solvent used to test CLOT and MOMF was a combination of 60:40 v/v acetonitrile and phosphate buffer (pH 4.0). A Shimpack ODS C18 column (4.6 mm × 250 mm, 5 µm) was utilized for this purpose. This approach was tested with a detection wavelength of 249 nm and a flow rate of 1 mL/min. The mobile phase was optimized utilizing a 3 2 full factorial design (quadratic model). The International Conference on Harmonization strategies were used to validate the methodology. The cream formulation comprising both the drugs underwent force degradation study. CLOT was determined to have an acceptable linearity range of 50–600 µg/mL, whereas MOMF had a linearity range of 5–60 µg/mL. The method demonstrated good sensitivity, with detection limit and quantification limit 3.97 and 12.04 µg/mL for CLOT along with 1.14 and 3.45 µg/mL for MOMF. The established methodology was determined to be both accurate (recovery between 98% and 102%) and precise (% RSD < 2). The degradation studies aimed to confirm the efficient separation of CLOT and MOMF from their degradation products. Chromatograms of stressed samples confirmed that degradation products did not interfere with the peaks of the active components.
- Open Access
- 28 April 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (2) , 330-355
Exploring the Therapeutic Potential of 1,3-Benzimidazole: An Auspicious Heterocyclic Framework
The scientific study of benzimidazole derivatives has advanced steadily due to its fascinating chemical structure with wide range of biological activities. This unique organic nitrogen bridged heterocyclic compounds have found applications in pharmaceuticals, organometallics, and natural products, establishing themselves as indispensable tools for medicinal chemists. To gather scientific insights, comprehensive searches were conducted across databases such as Google, PubMed, Scopus, Google Scholar, and others. This research highlights pharmacological profile of 1,3˗Benzimidazole derivatives while examining their pharmacological characteristics and therapeutic potential, including antimicrobial, anticancer, antiviral, antidiabetic, antitubercular, antifungal, antimalarial, and anti-inflammatory effects. The 1,3˗benzimidazole scaffold is a cornerstone in numerous natural and pharmaceutical products and serves as the basis for several clinically approved drugs, such as the antihistamine drug lerisetron, the antiviral agent maribavir, the proton pump inhibitor omeprazole, the anthelmintic triclabendazole, and the Anti˗fungal chlormidazole. Recent developments in the pharmacological uses of 1,3˗benzimidazole derivatives in a variety of therapeutic domains are explained in this thorough study. Furthermore, detailed molecular docking studies are included, providing medicinal chemists with valuable insights and a robust framework for future drug development efforts.
- 28 April 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (2) , 330-355
Open AccessExploring the Therapeutic Potential of 1,3-Benzimidazole: An Auspicious Heterocyclic Framework
The scientific study of benzimidazole derivatives has advanced steadily due to its fascinating chemical structure with wide range of biological activities. This unique organic nitrogen bridged heterocyclic compounds have found applications in pharmaceuticals, organometallics, and natural products, establishing themselves as indispensable tools for medicinal chemists. To gather scientific insights, comprehensive searches were conducted across databases such as Google, PubMed, Scopus, Google Scholar, and others. This research highlights pharmacological profile of 1,3˗Benzimidazole derivatives while examining their pharmacological characteristics and therapeutic potential, including antimicrobial, anticancer, antiviral, antidiabetic, antitubercular, antifungal, antimalarial, and anti-inflammatory effects. The 1,3˗benzimidazole scaffold is a cornerstone in numerous natural and pharmaceutical products and serves as the basis for several clinically approved drugs, such as the antihistamine drug lerisetron, the antiviral agent maribavir, the proton pump inhibitor omeprazole, the anthelmintic triclabendazole, and the Anti˗fungal chlormidazole. Recent developments in the pharmacological uses of 1,3˗benzimidazole derivatives in a variety of therapeutic domains are explained in this thorough study. Furthermore, detailed molecular docking studies are included, providing medicinal chemists with valuable insights and a robust framework for future drug development efforts.
- Open Access
- 1 January 2025
- Published by CSIR-National Institute of Science Communication and Policy Research (NIScPR) in Indian Journal of Biochemistry and Biophysics
- Vol. 62 (6) , 584-595
Exploring benzothiazole derivatives: Promising PLK1 Inhibitors for cancer therapy through Virtual screening, Molecular docking, and ADMET evaluation
The search for effective cancer therapies has driven significant interest in targeting Polo-like kinase 1 (PLK1), a crucial regulator of cell cycle progression, mitosis, epithelial-mesenchymal transition, autophagy, and DNA replication. Over expression of PLK1 is frequently observed in various cancers, making it a promising therapeutic target. Given the need for novel and potent PLK1 inhibitors, this study investigates the benzothiazole-containing drug 5f-203, known for inducing cell cycle arrest, as a potential PLK1 inhibitor. Using the PubChem database, novel PLK1 inhibitors were identified with 5f-203 (clinical trial, Phase 1) as the reference molecule. A comprehensive computational approach, including virtual screening, ligand and protein preparation, grid building, and molecular docking, was employed to evaluate co-crystallized ligand 5f-203, screened molecules, and newly designed compounds (N1-N6). Protein validation using ProSA (-7.9), ERRAT (95.36%), and the Ramachandran plot (84.1% residues in favored regions) confirmed model reliability. Lipinski’s rule was applied as an additional filter, and molecular docking revealed binding affinity values ranging from -8.82 to -7.73 kcal/mol, with molecule P1 exhibiting the highest affinity (-8.82 kcal/mol). Interaction analysis showed that 5f-203 formed H-bonds with Arg120 and NH2, while Ala66, Arg122, and Ile118 contributed to pi-alkyl interactions. Newly designed compounds (N1-N6) outperformed 5f-203 in docking scores, with synthetic accessibility below 4.5. ADMET studies further supported their drug-like potential. These findings suggest that the top 10 screened hits and newly designed benzothiazole derivatives hold promise as PLK1 inhibitors, offering a potential avenue for cancer therapy.
- 1 January 2025
- Published by CSIR-National Institute of Science Communication and Policy Research (NIScPR) in Indian Journal of Biochemistry and Biophysics
- Vol. 62 (6) , 584-595
Open AccessExploring benzothiazole derivatives: Promising PLK1 Inhibitors for cancer therapy through Virtual screening, Molecular docking, and ADMET evaluation
The search for effective cancer therapies has driven significant interest in targeting Polo-like kinase 1 (PLK1), a crucial regulator of cell cycle progression, mitosis, epithelial-mesenchymal transition, autophagy, and DNA replication. Over expression of PLK1 is frequently observed in various cancers, making it a promising therapeutic target. Given the need for novel and potent PLK1 inhibitors, this study investigates the benzothiazole-containing drug 5f-203, known for inducing cell cycle arrest, as a potential PLK1 inhibitor. Using the PubChem database, novel PLK1 inhibitors were identified with 5f-203 (clinical trial, Phase 1) as the reference molecule. A comprehensive computational approach, including virtual screening, ligand and protein preparation, grid building, and molecular docking, was employed to evaluate co-crystallized ligand 5f-203, screened molecules, and newly designed compounds (N1-N6). Protein validation using ProSA (-7.9), ERRAT (95.36%), and the Ramachandran plot (84.1% residues in favored regions) confirmed model reliability. Lipinski’s rule was applied as an additional filter, and molecular docking revealed binding affinity values ranging from -8.82 to -7.73 kcal/mol, with molecule P1 exhibiting the highest affinity (-8.82 kcal/mol). Interaction analysis showed that 5f-203 formed H-bonds with Arg120 and NH2, while Ala66, Arg122, and Ile118 contributed to pi-alkyl interactions. Newly designed compounds (N1-N6) outperformed 5f-203 in docking scores, with synthetic accessibility below 4.5. ADMET studies further supported their drug-like potential. These findings suggest that the top 10 screened hits and newly designed benzothiazole derivatives hold promise as PLK1 inhibitors, offering a potential avenue for cancer therapy.
- Open Access
- 30 August 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (4) , 970-975
Development of a Chromatographic Technique for Quantification of Drotaverine Hydrochloride and Diclofenac Potassium
Oriental Journal of Chemistry is a peer reviewed quarterly research journal of pure and applied chemistry. It publishes standard research papers in almost all thrust areas of current chemistry of academic and commercial importance. It provides a platform for rapid publication of quality research papers, reviews and chemistry letters. Oriental Journal of Chemistry is abstracted and indexed in almost all reputed National and International agencies.
- 30 August 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (4) , 970-975
Open AccessDevelopment of a Chromatographic Technique for Quantification of Drotaverine Hydrochloride and Diclofenac Potassium
Oriental Journal of Chemistry is a peer reviewed quarterly research journal of pure and applied chemistry. It publishes standard research papers in almost all thrust areas of current chemistry of academic and commercial importance. It provides a platform for rapid publication of quality research papers, reviews and chemistry letters. Oriental Journal of Chemistry is abstracted and indexed in almost all reputed National and International agencies.
- Open Access
- 30 June 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (3) , 657-669
A-Review on Anticancer Agents: Conventional Drugs and Novel Target Specific Inhibitors
The second-most common reason for death globally and a significant issue for human health is cancer. The focus of the current review is to discuss cancer treatment and issues with anti-cancer medications. Nearly all cell types can develop cancer, a very varied group of approximately 200 illnesses with at least one factor in common “uncontrolled cellular development” that results in aberrant cell proliferation. In solid tumors, cancerous cells may remain localized or in situ at the location of the initial lesion, or they may become locally progressed or metastatic to distant site. Ninety percent of all cancer-related fatalities are due to by metastasis. It is the primary determinant of whether malignancy is high-risk, requiring aggressive treatment, or low-risk, curable by active surveillance, surgical removal, or adjuvant therapy. Recent advancements in computational drug discovery methodologies have not only produced important insights into the field of cancer therapy but have also had a significant and impact on the development of novel anticancer medications. Within the scope of this review, we investigated potential therapeutic targets for anti-cancer drugs.
- 30 June 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (3) , 657-669
Open AccessA-Review on Anticancer Agents: Conventional Drugs and Novel Target Specific Inhibitors
The second-most common reason for death globally and a significant issue for human health is cancer. The focus of the current review is to discuss cancer treatment and issues with anti-cancer medications. Nearly all cell types can develop cancer, a very varied group of approximately 200 illnesses with at least one factor in common “uncontrolled cellular development” that results in aberrant cell proliferation. In solid tumors, cancerous cells may remain localized or in situ at the location of the initial lesion, or they may become locally progressed or metastatic to distant site. Ninety percent of all cancer-related fatalities are due to by metastasis. It is the primary determinant of whether malignancy is high-risk, requiring aggressive treatment, or low-risk, curable by active surveillance, surgical removal, or adjuvant therapy. Recent advancements in computational drug discovery methodologies have not only produced important insights into the field of cancer therapy but have also had a significant and impact on the development of novel anticancer medications. Within the scope of this review, we investigated potential therapeutic targets for anti-cancer drugs.
- 5 July 2021
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- Vol. 33 (35A) , 123-133
Synthesis, Characterization and Biological Evaluation of Thiazolidinedione Derivative as Novel Antidiabetic Agents
Thiazolidinedione derivative have Antihyperglycemic activity, they are agonists for the peroxisome proliferator-activated receptor (PPAR), which controls glucose synthesis, transport, and utilization via regulating the transcription of insulin-responsive genes. A number of novel insulin sensitizers are currently being researched. Several of these are derivatives of Thiazolidinedione, but others have different chemical structures. In this work, we created some new Thiazolidinedione derivative based on structure–activity relationship as closely as feasible. The Thiazolidine-2,4-Dione derivatives were manually developed and synthesized using the proper synthetic techniques, then tested in vitro for antihyperglycemic action using the Sucrose loading model (SLM) and the Alloxan induced diabetes model (AIDM). The newly synthesized Thiazolidine-2,4-Dione derivative was characterized using infrared (IR) and proton (H) nuclear magnetic resonance. In this study we found that Compound M-4 has a lot of antihyperglycemic action, thus it's a good idea to think about using it as a lead material for the creation of anti-diabetic drugs.
- 5 July 2021
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- Vol. 33 (35A) , 123-133
Synthesis, Characterization and Biological Evaluation of Thiazolidinedione Derivative as Novel Antidiabetic Agents
Thiazolidinedione derivative have Antihyperglycemic activity, they are agonists for the peroxisome proliferator-activated receptor (PPAR), which controls glucose synthesis, transport, and utilization via regulating the transcription of insulin-responsive genes. A number of novel insulin sensitizers are currently being researched. Several of these are derivatives of Thiazolidinedione, but others have different chemical structures. In this work, we created some new Thiazolidinedione derivative based on structure–activity relationship as closely as feasible. The Thiazolidine-2,4-Dione derivatives were manually developed and synthesized using the proper synthetic techniques, then tested in vitro for antihyperglycemic action using the Sucrose loading model (SLM) and the Alloxan induced diabetes model (AIDM). The newly synthesized Thiazolidine-2,4-Dione derivative was characterized using infrared (IR) and proton (H) nuclear magnetic resonance. In this study we found that Compound M-4 has a lot of antihyperglycemic action, thus it's a good idea to think about using it as a lead material for the creation of anti-diabetic drugs.